期刊文献+

内皮细胞抑制素酵母工程菌的高密度发酵及产物纯化和活性分析 被引量:2

High Density Culture of P. pastoris GS115(pPIC9K-EDN)Habouring Endostatin Gene and Purification and Bioactivity Analysis of Product
下载PDF
导出
摘要 用 30升发酵罐研究了内皮细胞抑制素 (EDN)酵母工程菌P .pastorisGS115 (pPIC9K EDN)的高密度发酵工艺 ,摸索出发酵培养基 ,pH ,诱导时间等对菌体生长和基因表达的影响 .根据所确定的最适条件进行发酵 ,通过补料和甲醇诱导 4 8h后 ,工程菌GS115 (pPIC9K EDN)生物量的A60 0 值达到 2 5 0 ,分泌量为 15 0mg L .发酵液经StreamlineSP ,SepharoseSPFF离子交换柱和Sepharose HeparinHiTrap亲和柱纯化 ,产物纯度达 97%以上 ,回收率为 6 0 % .Western印迹结果表明 ,酵母工程菌GS115 (pPIC9K EDN)表达的重组人内皮细胞抑制素具有天然EDN的免疫原性 .MTT法和抑癌实验结果显示 :纯化产物能抑制人脐静脉内皮细胞的增殖并能抑制移植于小鼠的黑色素瘤的生长 ,其平均抑瘤率是 94 2 % . The high cell density of P. pastoris GS115(pPIC9K EDN ) strain harboring human endostatin (EDN) was cultured in a 30 liter fermentor and the effect of media, pH and induction time on cell growth and gene expression were determined. By fed batch fermentation and methanol induction for 48 hours,the biomass A 600 of GS115(pPIC9K EDN ) reached 250, the secreted EDN was 150 mg/L. The fermentation product was purified to 97% by Streamline SP and Sepharose SP F F cation exchanger column and Sepharose\|Heparin Hi Trap affinity chromatography. The total recovery was 60%. Western blot analysis demonstrated that the purified product reacted with anti mEDN antibody. The purified product specifically inhibited the proliferation of human umbilical vein endothelial cells(ECV304) by 68.9% at 2 μg/ml. The purified endostatin also suppressed in vivo growth of B16 murine melanoma by 94 2% at a dose of 10 mg/(kg·d).
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2004年第2期224-228,共5页 Chinese Journal of Biochemistry and Molecular Biology
基金 广东省重点科技项目 (No .2KMO2 5 0 2G)资助~~
关键词 内皮细胞抑制素 酵母工程菌 发酵 产物 纯化 毕赤酵母 生物活性 human endostatin,Pichia pastoris, high density culture, purification, bioactivity
  • 相关文献

参考文献14

  • 1Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 1989, 82:4 - 6
  • 2Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86:353 - 364
  • 3Harris A L. Are angiostatin and endostatin cures for cancer? Lancet,1998, 351: 1598 - 1599
  • 4O'Reilly M S, Boehm T, Shing Y, Fukai N, Vasios G, Lane W S,Flynn E, Birkhead J R, Olsen B R, Folkman J. Endostatin: An endogeneous inhibitor of angiogenesis and tumor growth. Cell, 1997,88: 277 - 285
  • 5Boehm T, Folkmam J, Browder T, O' Reilly M S. Antiangiogenic therapy of experiment cancer does not induce acquired drug resistance.Nature, 1997,390: 404 - 407
  • 6Blank W R, Agner R C. Tumor regression after endostatin therapy.Nature, 1998, 391:450
  • 7Hohenester E, Sasaki T, Olsen B R, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J, 1998,17:1656 - 1664
  • 8Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L,Lindahl U, Hohenester E, Timpl R. Structure basis and potential role of heparin/heparin sulfate binding to the angiogenesis inhibitor endostatin. EMBO J, 1999, 18:6240 ~ 6248
  • 9Suhakar A, Sugimoto H, Yang C Y, Lively J, Zeisberg M, Kalluri R.Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αVβ3 and α5β1 integrins. Proc Natl Acad Sci USA, 2003, 100(8) :4765 ~ 4771
  • 10Nilsen S L, Deford M E, Prorok M, Chibber B A, Bretthauer R K,Castellino F J. High level secretion in Pichia pastoris and biochemical characterization of the recombinant kringle 2 domain of tissue-type plasminogen activator. Biotechnol Appl Biochem, 1997,

二级参考文献11

  • 1吴青.肝细胞生长因子[J].生命的化学,1996,16(2):15-18. 被引量:1
  • 2Shiota G,Proc Nat Acad Sci USA,1992年,89卷,373页
  • 3Folkman J,Watson K,Ingber D,Hanahan D.Induction of angiogenesis during the transition from hyperplasia to neoplasia[].Nature.1989
  • 4Harris A L.Are angiostatin and endostatin cures for cancer[].The Lancet.1998
  • 5O’Reilly M S et al.Endostatin: An endogenous inhibitor of angiogenesis and tumor growth[].Cell.1997
  • 6Boehem T,Folkman J,Browder T,O’Reilly M S.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance[].Nature.1997
  • 7Standker L,Schrader M,Kanse S M,Jurgens M,Forssmann W G,Preissner K T.Isolation and characterization of the circulating form of human[].FEBS Letters.1997
  • 8Sasaki T,Fukai N,Mann K,Gohring W,Olsen B R,Timpl R.Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin[].EMBO Journal.1998
  • 9Hohenester E,Sasaki T,Olsen B R,Timpl R.Crystal structure of the angiogenesis inhibitor endostatin at 1. 5 resolution[].EMBO Journal.1998
  • 10Black W R.Tumor regression after endostatin therapy[].Nature.1998

共引文献6

同被引文献23

  • 1O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth [J].Cell, 1997, 88:277.
  • 2Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J]. Nature, 1997,390: 404.
  • 3James P, Thomas, Rhoda Z, etal. Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors [J]. J Clinl Oncology, 2003, 21(2): 223.
  • 4Roy S, Herbst, Nizar A, et al. Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin[J]. Journal of Clinical Oncology, 2002, 20(18): 3804.
  • 5Christoph M, James P, Thomas, et al. Tissue Examination to Monitor Antiangiogenic Therapy [J]. Clin Cancer Res,2001, 7:3366.
  • 6Xiaojun H, Michael KK Wong, Qun Z, et al. Soluble Recombinant Endostatin Purified from Escherichia coli: Antiangiogenic Activity and Antitumor Effect [J]. Cancer Res,2001,61: 478.
  • 7Dhanabal M, Ramchandran R, Volk R, et al. Endostatin:yeast production, mutants, and antitumor effect in renal cell carcinoma[J]. CancerRes, 1999, 59: 189.
  • 8Watergam HR, Digan ME, Koutz PJ, etal. Isolation of the Pichia pastores glyceraldehydes-3-phisphate degydrogenase gene and regulation and use of its promoter[J]. Gene, 1997,186: 37.
  • 9Sasaki T, Fukai N, Mam K, et al. Structure, function and tissue forms of the c-terminal globular domain of collagen ⅩⅤⅢ containing the angiogenesis inhibitor endostatin[J]. EMBO J, 1998,17:4249.
  • 10Thomas B, Michael S, O'Reilly, et al. Zinc-binding of En dostatin is essiential for its antiangiogenic activity [J].Bilchem Biophys Res Commun, 1998,252: 190.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部